Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia — KADOAH  

Hemophilia A Clinical Trial

Official title: Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia

Status Completed

Clinical Trial Summary

Hemophilia is a rare X-linked bleeding disorder responsible for deficiency of coagulation factor VIII (FVIII) or IX (FIX). The main clinical manifestation is increased bleeding throughout the life which is directly correlated to the severity of the hemophilia, either mild (FVIII/FIX: 6-40), moderate (FVIII/FIX: 1-5%), or severe (FVIII/FIX<1%). Thanks to new therapies and long-term specialized follow-up by hemophilia treatment centers (HTCs), the life expectancy of patients with hemophilia (PWH) has improved considerably, even reaching that of the general population (1).

Healthcare professionals are so more confronted to PWH with age-related pathologies, in particular cardiovascular pathologies such as atrial fibrillation, acute coronary syndromes or thromboembolic events (arterial or venous). It is now recommended in PWH that an anticoagulant treatment (AC) be prescribed as in the general population (2,3,4). The recently published COCHE study demonstrated a significantly increased risk of bleeding in PWH receiving antithrombotic treatment. This bleeding risk depended significantly on the type of antithrombotic treatment, which was higher for anticoagulant vs antiplatelet drugs, on basal levels of FVIII or FIX, and on the HAS-BLED score (5).

Nowadays in the general population, among anticoagulant drugs, direct oral anticoagulants (DOACs) are preferred to vitamin K antagonist (KVA), thanks to their reduced risk of bleeding particularly intracerebral bleeding and better anticoagulant stability over time (6). However, we do not yet know precisely whether DOACs could occupy the same place in the PWH population because of the lack of evidence-based data due to the very small number of these patients, although some authors already recommend them over KVA. The KADOAH study was therefore set up to try to provide initial elements for future recommendations. Its main objective was to compare the level of bleeding risk of PWH treated with VKA vs DOACs.

Clinical Trial Description

The KADOAH study is an observational, retrospective and multicenter case-control study conducted in Hemophilia Treatment Centers (HTC) of the French Grand-Ouest interregion including HTCs of Brest, Caen, Le Mans, Nantes, Rennes and Rouen.

Objectives of the KADOAH study are:

• To compare the risk of bleeding events of 2 types of long-term anticoagulant treatment, vitamin K antagonists (VKA) versus Direct Oral Anticoagulants (DOAC), in patients with hemophilia,

• To describe the different types of bleeding events that occur during anticoagulant treatments in patients with hemophilia,

• To investigate for the influence of the HAS-BLED score on the risk of bleeding events in patients with hemophilia receiving a long-term anticoagulant treatment.

Inclusion criteria:

• Cases :

• Males at any ages with hemophilia of any severity and of any type,

• Patients having received or receiving a long-term anticoagulant treatment (during at least 6 consecutive months) during the period from 2012 to 2021,

• Regular follow-up in a hemophilia treatment center.

• Controls cross-matched with cases on :

• Age (+/- 5 years),

• Hemophilia type (either A or B)

• Hemophilia severity (for mild hemophilia: same basal factor level +/- 5%),

• HAS-BLED score (same score +/- 1).

Exclusion criteria:

• Lost to medical follow-up,

• Refusal to participate in the study,

• Unable to understand the study's French letter of non-opposition and information.

Collected data:

All data collected in this study were issued from the medical files at the moment of the inclusion in the study. They include:

• The age,

• The hemophilia's type,

• The hemophilia's severity and last basal factor VIII or IX level,

• The treatment with anticoagulant drug for cases including :

• Type of drug (either VKA or DOAC)

• Duration of treatments

• Treatments dosages,

• Compliance of treatments,

• Indications,

• If stopped prematurely, reasons for stopping.

• The occurrence of severe bleeding events (SBE) following the ISTH definition (7):

• The number of SBE per patient,

• The types of SBE,

• The treatment of SBE.

• The HAS-BLED score calculated with the presence or absence of the following items:

• High arterial pressure,

• Abnormal renal and/or liver functions,

• Hemorrhagic stroke,

• Bleeding antecedent,

• Age >65 years,

• Treatments altering the hemostasis (out of the anticoagulants) and/or alcohol intoxication.

• The CHA2DS-VASc score calculated with the presence or absence of the following items:

• Cardiac insufficiency/left ventricular dysfunction,

• High arterial pressure,

• Age ≥ 75 years, or age = 65 - 74 years,

• Diabetes,

• History of thrombotic events (transient ischemic cerebral attack or stroke, venous thromboembolic events)

• Associated treatment with a proton pomp inhibitor or other gastric protector,

Statistical analyses Descriptive characteristics were analyzed with median values, their 25-75% interquartile ranges (IQR) and minimum-maximum values (MIN-MAX), or mean values with standard deviation (SD). The Fisher's exact test will be performed to compare proportions in contingency tables and the t Student test to compare continuous variables. An approximate 95% confidence interval will be determined (95% CI) for every statistical analysis and a p-value <0.05 will be considered statistically significant. The GraphPad v7.0 (Prism Software Inc. San Diego CA) will be used to perform the statistical analyses. ;

Related Conditions & MeSH terms

• Anticoagulant-induced Bleeding
• Hemophilia A
• Hemophilia B
• Hemorrhage

• NCT number: NCT05804734
• Study type: Observational
• Source: Groupe Maladies hémorragiques de Bretagne
• Status: Completed
• Start date: June 1, 2021
• Completion date: December 31, 2021